Clinical implications of UGT1A1 *28 genotype testing in colorectal cancer patients
dc.contributor.author | Shulman, Katerina | en_US |
dc.contributor.author | Cohen, Ilana | en_US |
dc.contributor.author | Barnett‐griness, Ofra | en_US |
dc.contributor.author | Kuten, Abraham | en_US |
dc.contributor.author | Gruber, Stephen B. | en_US |
dc.contributor.author | Lejbkowicz, Flavio | en_US |
dc.contributor.author | Rennert, Gad | en_US |
dc.date.accessioned | 2011-11-10T15:32:15Z | |
dc.date.available | 2012-09-04T15:27:28Z | en_US |
dc.date.issued | 2011-07-15 | en_US |
dc.identifier.citation | Shulman, Katerina; Cohen, Ilana; Barnett‐griness, Ofra ; Kuten, Abraham; Gruber, Stephen B.; Lejbkowicz, Flavio; Rennert, Gad (2011). "Clinical implications of UGT1A1 *28 genotype testing in colorectal cancer patients." Cancer 117(14): 3156-3162. <http://hdl.handle.net/2027.42/86858> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/86858 | |
dc.description.abstract | BACKGROUND: Metastatic colorectal cancer is frequently treated with irinotecan, a topoisomerase‐I inhibitor. The UGT1A1 gene encodes for an enzyme that metabolizes irinotecan, and its genetic variants were shown to be associated with increased drug toxicity. We evaluated clinical outcomes associated with the UGT1A1 *28 variant. METHODS: The study included 329 colorectal cancer patients from the Israeli population‐based Molecular Epidemiology of Colorectal Cancer study who were treated with a chemotherapy regimen that included irinotecan. Patients with metastases or disease recurrence were followed up for a median period of 2 years after occurrence of the event. Study end points were appearance of grade 3‐4 hematological and gastroenterological toxicity, hospitalization due to toxic events (mostly neutropenia, fever, diarrhea, or vomiting), length of hospitalization, and overall survival. UGT1A1 *28 was genotyped from peripheral blood DNA by fragment analysis and reported as number of TATA sequence repeats in the promoter of the gene. RESULTS: The 7/7 variant of UGT1A1 *28 was detected in 11.9% of the 329 participants. Grade 3‐4 hematological toxicity was significantly higher in 7/7 carriers compared with 6/7 and 6/6 carriers (48.0%,10.2%, and 7.7% respectively; P < .001), as was the risk of toxicity‐related hospitalization (45.8%, 25.3%, and 14.4% respectively; P = .001). Both short‐term death within 2 months of treatment start (12.8%, 5.2%, and 2.9%, respectively) and median overall survival (1.6, 2.0, and 2.4 years, respectively; P = .01) were significantly worse in the 7/7 carriers. The age/stage‐adjusted hazard ratio for patients with the 7/7 genotype compared with 6/6 was 1.7 (95% confidence interval, 1.1‐2.3). CONCLUSIONS: The UGT1A1 *28 7/7 genotype is strongly associated with severe hematological toxicity and higher hospitalization rate and predicts lower survival of colorectal cancer in users of irinotecan. Cancer 2011. © 2011 American Cancer Society. The UGT1A1 *28 7/7 genotype is strongly associated with severe toxicity and higher hospitalization rate and predicts lower survival of colorectal cancer in users of irinotecan. Genetic testing is recommended before initiation of treatment with irinotecan. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Irinotecan | en_US |
dc.subject.other | Colorectal Cancer | en_US |
dc.subject.other | UGT1A1 | en_US |
dc.subject.other | Toxicity, Survival | en_US |
dc.title | Clinical implications of UGT1A1 *28 genotype testing in colorectal cancer patients | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Departments of Internal Medicine, Epidemiology, and Human Genetics, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | CHS National Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel Medical Center and Bruce Rappaport Faculty of Medicine, Technion‐Israel Institute of Technology, Haifa, Israel | en_US |
dc.contributor.affiliationother | Oncology Center, Rambam Medical Center, Haifa, Israel | en_US |
dc.contributor.affiliationother | Department of Community Medicine and Epidemiology, Carmel Medical Center, 7 Michal Street, Haifa 34362, Israel | en_US |
dc.identifier.pmid | 21287524 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/86858/1/25735_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.25735 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003; 361: 2235 ‐ 2242. | en_US |
dc.identifier.citedreference | Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol. 2009; 27: 2604 ‐ 2614. | en_US |
dc.identifier.citedreference | Armand JP, Extra YM, Catimel G, Abigerges D, Marty M, Clavel M. Rationale for the dosage and schedule of CPT‐11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Ann Oncol. 1996; 7: 837 ‐ 842. | en_US |
dc.identifier.citedreference | Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008; 99: 1239 ‐ 1245. | en_US |
dc.identifier.citedreference | Innocenti F, Ratain MJ. “Irinogenetics” and UGT1A: from genotypes to haplotypes. Clin Pharmacol Ther. 2004; 75: 495 ‐ 500. | en_US |
dc.identifier.citedreference | Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol. 2009; 27: 2457 ‐ 2465. | en_US |
dc.identifier.citedreference | Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006; 24: 3061 ‐ 3068. | en_US |
dc.identifier.citedreference | Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan‐induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer. 2008; 112: 1932 ‐ 1940. | en_US |
dc.identifier.citedreference | Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002; 2: 43 ‐ 47. | en_US |
dc.identifier.citedreference | Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res. 2007; 13: 3269 ‐ 3275. | en_US |
dc.identifier.citedreference | Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan‐induced neutropenia: dose matters. J Natl Cancer Inst. 2007; 99: 1290 ‐ 1295. | en_US |
dc.identifier.citedreference | Biason P, Masier S, Toffoli G. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J Chemother. 2008; 20: 158 ‐ 165. | en_US |
dc.identifier.citedreference | Rhodes KE, Zhang W, Yang D, et al. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first‐line irinotecan. Drug Metab Lett. 2007; 1: 23 ‐ 30. | en_US |
dc.identifier.citedreference | Ferraldeschi R, Minchell LJ, Roberts SA, et al. UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate‐dose irinotecan. Pharmacogenomics. 2009; 10: 733 ‐ 739. | en_US |
dc.identifier.citedreference | Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan‐based chemotherapy. Cancer. 2006; 106: 1007 ‐ 1016. | en_US |
dc.identifier.citedreference | de Jong FA, Kehrer DF, Mathijssen RH, et al. Prophylaxis of irinotecan‐induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double‐blind,randomized, placebo‐controlled study. Oncologist. 2006; 11: 944 ‐ 954. | en_US |
dc.identifier.citedreference | FDA. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2005/020571s026ltr.pdf | en_US |
dc.identifier.citedreference | Toffoli G, Cecchin E, Gasparini G, et al. Genotype‐driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28: 866 ‐ 871. | en_US |
dc.identifier.citedreference | Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence‐based review. Genet Med. 2009; 11: 21 ‐ 34. | en_US |
dc.identifier.citedreference | Poynter JN, Gruber SB, Higgins PD, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352: 2184 ‐ 2192. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.